Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
about
Plague Vaccine Development: Current Research and Future TrendsMutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccinesLcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plaguePilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.YopE specific CD8+ T cells provide protection against systemic and mucosal Yersinia pseudotuberculosis infectionOral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plagueIntranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1)DNA immunization.Plague vaccines: current developments and future perspectives.Plague Vaccines: Status and Future.A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis.Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model.
P2860
Q28066875-E6C119D1-13BF-478E-BA59-27DBE3D72A8BQ28678943-3C8D3E9F-E99F-47D3-8692-B18339FB143AQ34298699-93EA8D91-2E13-4DA9-BAA2-A5DE66470DC1Q35091255-15EEC0AC-67B3-483B-B96D-A2E07477C93BQ35826610-F1D2F3EF-4228-4BC4-876A-DA6CB092EEB2Q36283058-B52E648A-EBDD-4A35-825F-AE9057F42081Q36372952-608C020E-BB1F-4F20-97B9-A3E81EE071D3Q36911486-3A4FDB84-3C59-417A-80F4-E9E047723EEBQ37530471-B824CA91-2301-4E6D-B213-980E90F894C3Q37576264-3DF68988-8F08-414A-A413-3D74F92C9C34Q38514208-070A0234-2489-49DD-9E99-8EE8AA1757B3Q38813137-7167BFCA-6035-4B3B-B1AD-DCAC87FB58D5Q40140655-5092FD91-2B87-4F18-8068-E881AEC1B001Q41400297-8672C427-B5D5-45D5-8DDD-4D22434A6270
P2860
Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@ast
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@en
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@nl
type
label
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@ast
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@en
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@nl
prefLabel
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@ast
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@en
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@nl
P2093
P2860
P1433
P1476
Involvement of CD8+ T cell-med ...... hal Yersinia pestis challenge.
@en
P2093
P2860
P304
P356
10.1016/J.VACCINE.2010.12.062
P407
P577
2011-01-01T00:00:00Z